CN104479019A - Anti-CTLA-4 humanized antibody - Google Patents
Anti-CTLA-4 humanized antibody Download PDFInfo
- Publication number
- CN104479019A CN104479019A CN201410838544.5A CN201410838544A CN104479019A CN 104479019 A CN104479019 A CN 104479019A CN 201410838544 A CN201410838544 A CN 201410838544A CN 104479019 A CN104479019 A CN 104479019A
- Authority
- CN
- China
- Prior art keywords
- antibody
- ctla
- human antibody
- variable region
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to the technical field of biology, and in particular relates to an anti-CTLA-4 humanized antibody. The anti-CTLA-4 humanized antibody is characterized in that the amino acid sequence of a variable region of a heavy chain of the antibody is shown as SEQ ID NO: 2 or is a conserved variation sequence; the amino acid sequence of a variable region of a light chain of the antibody is shown as SEQ ID NO: 4 or is a conserved variation sequence. The anti-CTLA-4 humanized antibody shows relatively high expression quantity in mammalian cells, and is obvious in affinity with CTLA-4 and able to inhibit the combination of a ligand and a receptor.
Description
Technical field
The present invention relates to biological technical field, particularly relate to a kind of anti-CTLA-4 human antibody.
Background technology
It is need various kinds of cell and molecule jointly to participate in that immunity system plays immunne response, co-operating complex process.Wherein, the lymphocytic activation of T is the important component part of this response.For making T lymphocyte activator, two class signals must be delivered to the T lymphocyte of quiescent stage.First kind signal be antigen presenting cell (APC) by antigen presentation to the φt cell receptor of T lymphocytic cell surface (TcR), thus give the specificity of T lymphocyte immunity response.Equations of The Second Kind signal is nonspecific costimulatory signal, regulates and controls the magnitude of immunne response, and this is realized by the accessory receptor on T lymphocyte, and study discovery at present, these accessory receptors include CD28, CTLA-4, PD-1 etc.
Cytotoxic t lymphocyte-associated antigen 4 (cytotoxic T lymphocyte-associated antigen-4, CTLA-4) CD152 is had another name called, it is a kind of leukocyte differentiation antigen, at a kind of transmembrane receptor of bone-marrow-derived lymphocyte surface expression of CD4+ and the CD8+T lymphocyte activated and activation, participate in immunoreactive regulating effect.CTLA-4 and CD28 has identical part B7-1 and B7-2, although the number of the T lymphocytic cell surface CTLA-4 of activation only has the avidity of 3% ~ 5%, CTLA-4 and B7 of CD28 stronger than CD28 10 ~ 50 times.Research finds the antagonist of CTLA-4 as CD28, suppresses the combination of B7 and CD28, thus reduces secretion and the blocking immunity cell proliferation of IL-2, plays the effect interrupting t cell activation.
Using the target spot of CTLA-4 as cancer immunotherapy, utilize monoclonal antibody in conjunction with CTLA-4, CTLA-4 and B7 can be blocked combine, T lymphocyte is stoped to suppress the generation of signal, thus the peripheral immune tolerance of break immune system against its own organism, promote the lymphocytic activation and proliferation of T, and cytokine-expressing, raise immunity system active for the monitoring of tumour cell, strengthen the immune response of specificity antineoplastic.The anti-CTLA-4 monoclonal antibody Ipilimumab researched and developed by Bristol-Myers Squibb Co. in the recent period achieves historical breakthrough in melanomatous treatment late, phase III clinical trial confirms that this medicine can by total effectively life span extension four months of advanced melanoma patient nearly, 2 years survival rates improve 50% nearly, it is the medicine that first of being found effectively can extend the advanced melanoma patients overall survival phase, and to be used for the treatment of as monotherapy by FDA approval on March 25th, 2011 and can not to excise or the first of metastasis melanin tumor controls patient or non-patients undergoing chemotherapy, this is the major progress of malignant melanoma and malignant tumour immunotherapy.Have except remarkable effect except being proved to be in treatment malignant melanoma, anti-CTLA-4 monoclonal antibody is also in clinical study in the effect in the cancers such as nonsmall-cell lung cancer, prostate cancer, liver cancer, mammary cancer that is used for the treatment of.
Therefore research and develop novel anti-CTLA-4 monoclonal antibody, for the immunotherapy of cancer, make it have lower toxic side effect, better clinical drug effect, becomes current study hotspot, also will provide more medicament selection to patient.
Summary of the invention
Prior art in view of the above, the object of the invention is to the human antibody of the novel anti-CTLA-4 by human antibody library screening high-affinity, and verifies its correlation function, for solving the problems of the prior art.
For achieving the above object and other relevant objects, the invention provides a kind of anti-CTLA-4 human antibody, the aminoacid sequence of its antibody chain variable region is SEQ ID NO:4 or its conservative form variation sequence, and the aminoacid sequence of its antibody heavy chain variable region is SEQ ID NO:2 or its conservative form variation sequence.
Described anti-CTLA-4 human antibody can be the full length sequence of antibody, and also can be the fragment of anti-CTLA-4 human antibody, described fragment be Fab, Fab ', F (ab ')
2, Fv or scFv etc.
Preferably, described anti-CTLA-4 human antibody is people source.
Preferred, described anti-CTLA-4 human antibody is IgG
1, IgG
2or IgG
4type antibody.
The present invention further provides the derivative of described anti-CTLA-4 human antibody, described derivative is fragment, antibody/antibody fragment-factor fusion protein, the antibody/antibody fragment-chemical coupling thing of CTLA-4 human antibody; The fragment of described anti-CTLA-4 human antibody is Fab, Fab ', F (ab ')
2, Fv or scFv etc.
Described antibody/antibody fragment-factor fusion protein is specially antibody-factor fusion rotein or antibody fragment-factor fusion protein.
Described antibody/antibody fragment-chemical coupling thing is specially antibody-chemical coupling thing or antibody fragment-chemical coupling thing.
Second aspect present invention provides a kind of DNA molecular of separation, the encode described anti-heavy chain of CTLA-4 human antibody and/or the variable region of light chain or full length amino acid.
Third aspect present invention provides a kind of construct, the DNA molecular containing described separation.
Preferably, the multiple clone site structure that described construct is inserted into expression vector by the DNA molecular of described separation forms.
Expression vector in the present invention refers to bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell is viral, mammalian cell is viral as adenovirus, retrovirus or other carriers.
Preferred, described expression vector is selected from one or more the combination in pHLX101, pEE14.4 or pcDNA3.1.
Fourth aspect present invention provides a kind of expression system of monoclonal antibody, is transfected into constructing host cell forms by described construct.
Host cell in the present invention can be prokaryotic cell prokaryocyte, as bacterial cell; Or the eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.
Preferably, described host cell is selected from Chinese hamster ovary (Chinese Hamster Ovary (CHO)) clone, multiple COS clone, HeLa clone, myeloid cell series are as SP2/0 clone, NS0 clone, YB2/0 clone etc., and transform B-cell or hybridoma in one or more combination.
Fifth aspect present invention provides the preparation method of described anti-CTLA-4 human antibody, comprise the steps: under the condition of the described antibody of applicable expression, the expression system of the monoclonal antibody described in cultivation, thus give expression to described monoclonal antibody, be isolated and purified with described monoclonal antibody.
Host cell used in the present invention is prior art, directly obtain by commercial sources, substratum used in cultivation is also various conventional medium, and those skilled in the art rule of thumb can select the substratum be suitable for, and cultivate under the condition being suitable for host cell growth.When after host cell growth to suitable cell density, the promotor selected with the induction of suitable method (as temperature transition or chemical induction), cultivates for some time again by cell.Recombinant polypeptide in the above methods can be expressed or be secreted into extracellular in cell or on cytolemma.If needed, can utilize its physics, the albumen of being recombinated by various separation method abstraction and purification with other characteristic of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation process, combination by protein precipitant process (salting-out method), centrifugal, the broken bacterium of infiltration, super process, ultracentrifugation, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The present invention screens the gene order obtaining object antibody from the cell strain of Colony Culture, in order to build carrier for expression of eukaryon, can rebuild the activity of antibody after expression, obtain anti-CTLA-4 Humanized monoclonal antibodies.
Sixth aspect present invention provides the purposes of described anti-CTLA-4 human antibody on preparation CTLA-4 molecule blocking medicine.
Preferably, the purposes on described preparation CTLA-4 molecule blocking medicine is specially the purposes on preparation oncotherapy or diagnosing tumor class medicine.
Preferred, described tumour is melanoma.
Preferred further, described tumour is advanced melanoma.
A kind of pharmaceutical composition of seventh aspect present invention, comprises the described anti-CTLA-4 human antibody for the treatment of significant quantity.
Human antibody of the present invention can be used by any known mode compounding pharmaceutical composition in this area.This composition for activeconstituents, adds one or more medicine acceptable carriers, thinner, weighting agent, bonding agent and other vehicle with described human antibody, and this depends on administering mode and designed dosage form.Inorganic or the organic carrier of the treatment inertia that this area branch art personnel are known includes, but is not limited to lactose, W-Gum or derivatives thereof, talcum, vegetables oil, wax, fat, many antelopes based compound such as polyoxyethylene glycol, water, sucrose, ethanol, glycerine, like this, various sanitas, lubricant, dispersion agent, correctives.Moisturizing is cut to pieces, antioxidant, sweeting agent, tinting material, stablizer, salt, damping fluid is like this also can add wherein, these materials are as required for helping the stability of formula or contributing to improving activity or its biological effectiveness or produce acceptable mouthfeel or smell when oral, but the form of inhibitor its original chemical itself can be used in such a composition, or optionally use the form of the acceptable salt of its pharmacology, human antibody of the present invention can be individually dosed, or with various combination medicine-feeding, and combining form administration together with other healing potion.The composition of preparation like this can select any suitable mode well known by persons skilled in the art that inhibitor is carried out administration as required.
Anti-CTLA-4 human antibody provided by the present invention has higher expression amount in mammalian cell, and to the ability that CTLA-4 has obvious avidity and suppresses ligand-receptor to combine.
Accompanying drawing explanation
Fig. 1 is that the SDS-PAGE expressing the CTLA-4 recombinant protein that also purifying obtains analyzes.
Fig. 2 is the avidity capacity experimental of anti-CTLA-4 antibody.
Fig. 3 is that the ligand-receptor of anti-CTLA-4 antibody is in conjunction with Inhibition test.
Embodiment
Below by way of specific specific examples, embodiments of the present invention are described, those skilled in the art the content disclosed by this specification sheets can understand other advantages of the present invention and effect easily.The present invention can also be implemented or be applied by embodiments different in addition, and the every details in this specification sheets also can based on different viewpoints and application, carries out various modification or change not deviating under spirit of the present invention.
Before further describing the specific embodiment of the invention, should be understood that protection scope of the present invention is not limited to following specific specific embodiments; It is also understood that the term used in the embodiment of the present invention is to describe specific specific embodiments, instead of in order to limit the scope of the invention; In specification sheets of the present invention and claims, unless explicitly pointed out in addition in literary composition, singulative " ", " one " and " this " comprise plural form.
When embodiment provides numerical range, should be understood that except non-invention is otherwise noted, between two end points of each numerical range and two end points, any one numerical value all can be selected.Unless otherwise defined, the same meaning that all technology used in the present invention and scientific terminology and those skilled in the art of the present technique understand usually.Except the concrete grammar used in embodiment, equipment, material, according to those skilled in the art to the grasp of prior art and record of the present invention, any method of prior art that is similar with the method described in the embodiment of the present invention, equipment, material or that be equal to, equipment and material can also be used to realize the present invention.
Unless otherwise indicated, disclosed in the present invention experimental technique, detection method, preparation method all adopt the routine techniques of the molecular biology of the art routine, biological chemistry, chromatin Structure and analysis, analytical chemistry, cell cultures, recombinant DNA technology and association area.These technology are existing in existing document improves explanation, specifically can see the MOLECULAR CLONING:A LABORATORY MANUAL such as Sambrook, Second edition, Cold Spring HarborLaboratory Press, 1989and Third edition, 2001; Ausubel etc., CURRENT PROTOCOLS INMOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; The seriesMETHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATINSTRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODSIN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), AcademicPress, San Diego, 1999; With METHODS IN MOLECULAR BIOLOGY, Vol.119, ChromatinProtocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc.
Embodiment 1
Expression and purification people CTLA-4 extracellular region recombinant protein
Synthesis people CTLA-4-Fc fusion gene (being synthesized by Nanjing Genscript Biotechnology Co., Ltd.), wherein CTLA-4 gene order is SEQ ID NO:5, Fc gene order is SEQ ID NO:6, two sections of sequences connections are CTLA-4-Fc fusion gene, design forward and reverse primer are respectively: 5 '-ATCCGCCGGCAAGCCGCCACCATGGCTTGCCTTGGATTTCAGCGG-3 ' (SEQ ID NO:7) and 5 '-TCACTACGTATCATTTACCCGGAGACAGGGAGAGGCTC-3 ' (SEQ ID NO:8), the gene of coding CTLA-4-Fc fusion rotein is obtained for increasing, restriction endonuclease sites Ngo MIV and Sna BI is introduced respectively in the upstream and downstream of gene, PCR condition is 95 DEG C of 30s, 60 DEG C of 30s, 72 DEG C of 60s, 35 circulations, 72 DEG C extend 10min, archaeal dna polymerase is TAKARA Products.
PCR primer reclaims after (reclaiming test kit is Omega bio-tek Products) purifying through sepharose, add restriction enzyme Ngo MIV and Sna BI to carry out enzyme and cut, digestion products reclaims after reagent (Omega bio-tek Products) purifying through DNA and carries out ligation with the carrier pHLX101 (being built by Shanghai Henlius Biotech Co. Ltd., see Chinese patent 201210211812.1) with identical digestion with restriction enzyme.Connect product conversion to DH5 α intestinal bacteria, be coated on the 2YT nutrient agar containing 50 μ g/ml Pyocianils.The positive colony of acquisition is cultivated in containing the 2YT liquid nutrient medium of 50 μ g/ml Pyocianils, after Invitrogen company sequence verification, takes out greatly test kit (Omegabio-tek Products) with plasmid and extract positive colony plasmid.
Adopt polymine (Polyethylenimine, PEI) method is by plasmid DNA transfection in 293F cell, and transfection is after 6 hours, by cell centrifugation, change fresh 293freestyle Medium nutrient solution (GIBCO Products), continue shaking table and cultivate.Can observe cell after 24 and 48 hours, after transfection the 3rd day starts every day to cell counting, and expression time is generally 7-10 days, when viable cell density lower than 30% time harvested cell nutrient solution supernatant.Cell culture supernatant Protein A affinity column is carried out purifying, finally obtains people CTLA-4 extracellular region recombinant protein.The SDS-PAGE analytical results of the CTLA-4 recombinant protein that purifying obtains as shown in Figure 1.
Embodiment 2
The structure of anti-CTLA-4 human antibody carrier for expression of eukaryon and expression
The aminoacid sequence of antibody heavy chain variable region is SEQ ID NO:2, and the DNA sequences encoding used in the present embodiment is SEQ ID NO:1;
The aminoacid sequence of antibody chain variable region is SEQ ID NO:4, and the DNA sequences encoding used in the present embodiment is SEQ ID NO:3; (heavy chain and chain variable region gene synthesize by Nanjing Genscript Biotechnology Co., Ltd.)
PCR reaction is used to increase to the DNA sequences encoding of above-mentioned variable region of light chain and variable region of heavy chain, suitable restriction enzyme site is introduced at the gene two ends of antibody heavy chain variable region and variable region of light chain, wherein hold and 3 ' end introducing Ngo MIV and Sna BI restriction enzyme site respectively at antibody heavy chain variable region gene 5 ', forward and reverse primer sequences are respectively: 5 '-ACCTGCCGGCAAGCCGCCACCATGGGTTGGAGCCTCATCTTGCTCTTC-3 ' (SEQ IDNO:9) and 5 '-GCTCTACGTATCATTTACCTGGAGACAGGGAGAGGC-3 ' (SEQ ID NO:10), hold and 3 ' end introducing Ngo MIV and SnaB I respectively at antibody chain variable region gene 5 ', forward and reverse primer sequences are respectively: 5 '-ACCTGCCGGCAAGCCGCCACCATGGGTTGGAGCCTCATCTTGCTCTTC-3 ' (SEQ IDNO:9) and 5 '-GCATCTTACGTATTATTATGAACATTCTGTAAG-3 ' (SEQ ID NO:11).Adopt PCR reaction, condition is 95 DEG C of 30s, 60 DEG C of 30s, 72 DEG C of 60s, 35 circulations, and 72 DEG C extend 10min, and archaeal dna polymerase is TAKARA Products.After pcr amplification, PCR primer is reclaimed purifying through agarose gel electrophoresis.Chain variable region gene adds restriction enzyme Ngo MIV and SnaB I to carry out enzyme and cuts, heavy chain variable region gene adds restriction enzyme Ngo MIV and Sna BI to carry out enzyme and cuts, enzyme carries out purifying through DNA purification kit after cutting, and with the carrier pHLX101 of identical digestion with restriction enzyme.Connect product conversion to DH5 α intestinal bacteria, be coated on the 2YT nutrient agar containing 50 μ g/ml Pyocianils.The positive colony obtained is cultivated in containing the 2YT liquid nutrient medium of 50 μ g/ml Pyocianils, after Invitrogen company sequence verification, takes out greatly test kit extract positive colony plasmid with plasmid.
Utilize the Neon system of Invitrogen company, by linearizing plasmid DNA transfection to Chinese hamster ovary celI.Chinese hamster ovary celI after transfection carries out dilution colonized culture, containing 50 μm of ol methionine(Met) imino-s for sulfone (methionine sulfoximine, MSX) screen in 94113 substratum (IrvineScientific Products), thus obtain monoclonal cell system.
Tied up to by the monoclonal cell of acquisition and carry out shake-flask culture containing 50 μm of ol methionine(Met) imino-s in 94113 substratum of sulfone, expression time is generally 7-14 days, when viable cell density lower than 30% time harvested cell nutrient solution supernatant.Utilize the goat-anti people constant region of light chain of goat anti-human igg Fd (Meridian Products) and horseradish peroxidase-labeled to carry out double sandwich-ELISA method and detect the content of expressing antibody in supernatant, using untransfected supernatant as negative control, the IgG sterling of people is as standard substance.Experimental result shows, and expressing the target protein obtained by two antibody recognition, can have human IgG antibody's feature, and the human antibody expression amount built is at 200 ~ 500 μ g/ml, has higher expression level.Adopt Protein A affinity column separation and purification object antibody from cells and supernatant.
Embodiment 3
Anti-CTLA-4 human antibody Function Identification
Affinity of antibody is identified.Wrap preparing CTLA-4 recombinant protein in embodiment 1 by (working volume 30ul) in enzyme plate by 2 μ g/ml, 4 DEG C of hold over night.3 times are washed with the PBS (PBST) of the Tween 20 containing 0.05%.BSA room temperature with 0.1% closes 1 hour.Wash 3 times with PBST, the antibody that embodiment 2 prepares is mixed with 4 μ g/ml concentration, and carries out 3 times of gradient dilutions, totally 8 gradients, every hole adds 30 μ l, and room temperature leaves standstill 1 hour.Wash 3 times with PBST, add the goat-anti people constant region of light chain two anti-(Millipore Products) of the horseradish peroxidase-labeled that 30 μ l 1:4000 dilute, room temperature leaves standstill 1 hour.Wash 4 times with PBST, add TMB colour developing, and with the H of 2M
2sO
4termination reaction.With microplate reader reading at 450 nm.Can find out from result, screen the antibody obtained, to CTLA-4, there is obvious avidity, and its ability close with positive control Ipilimumab (Fig. 2).
Part-antibodies Inhibition test.Wrap preparing CTLA-4 recombinant protein in embodiment 1 by enzyme plate by 2 μ g/ml, 4 DEG C of hold over night.3 times are washed with PBST.BSA room temperature with 0.1% closes 1 hour.Wash 3 times with PBST, the antibody that embodiment 2 prepares is mixed with 2 μ g/ml concentration, and carries out 2 times of gradient dilutions, totally 10 gradients, mix with biotin labeled 2 μ g/ml B7-1 (justice sticks up Divine Land Products), join in enzyme plate, room temperature leaves standstill 1 hour.Wash 3 times with PBST, add the avidin-HRP (BostonBiochem Products) of 1:5000 dilution, room temperature leaves standstill 1 hour.Wash 4 times with PBST, add TMB colour developing, and with the H of 2M
2sO
4termination reaction.With microplate reader reading at 450 nm.As can be seen from the results, screen the combination that the antibody capable obtained suppresses CTLA-4 and its part B7-1, and its ability close with Ipilimumab (Fig. 3).
PBS formula is: potassium primary phosphate (KH2PO4): 0.27g, Sodium phosphate dibasic (Na2HPO4): 1.42g, sodium-chlor (NaCl): 8g, Repone K (KCl): 0.2g, add deionized water and be about the abundant stirring and dissolving of 800mL, then add concentrated hydrochloric acid and adjust pH to 7.4, last constant volume is to 1L.
In sum, the present invention effectively overcomes various shortcoming of the prior art and tool high industrial utilization.
Above-described embodiment is illustrative principle of the present invention and effect thereof only, but not for limiting the present invention.Any person skilled in the art scholar all without prejudice under spirit of the present invention and category, can modify above-described embodiment or changes.Therefore, such as have in art usually know the knowledgeable do not depart from complete under disclosed spirit and technological thought all equivalence modify or change, must be contained by claim of the present invention.
Claims (12)
1. an anti-CTLA-4 human antibody, the aminoacid sequence of its antibody heavy chain variable region is SEQ ID NO:2 or its conservative form variation sequence, and the aminoacid sequence of its antibody chain variable region is SEQ ID NO:4 or its conservative form variation sequence.
2. anti-CTLA-4 human antibody as claimed in claim 1, is characterized in that, described antibody is people source.
3. anti-CTLA-4 human antibody as claimed in claim 1, is characterized in that, described antibody is IgG
1, IgG
2or IgG
4type antibody.
4. the derivative of anti-CTLA-4 human antibody as claimed in claim 1, described derivative is the fragment of described anti-CTLA-4 human antibody, antibody/antibody fragment-factor fusion protein or antibody/antibody fragment-chemical coupling thing.
5. the derivative of anti-CTLA-4 human antibody as claimed in claim 4, is characterized in that, the fragment of described anti-CTLA-4 human antibody is Fab, Fab ', F (ab ')
2, Fv or scFv.
6. the DNA molecular be separated, the anti-heavy chain of CTLA-4 human antibody described in coding claim 1-3 arbitrary claim and/or the variable region of light chain or full length amino acid.
7. a construct, containing, for example the DNA molecular of separation according to claim 6.
8. a kind of construct as claimed in claim 7, is characterized in that, the multiple clone site structure being inserted into expression vector by the DNA molecular of separation according to claim 6 forms.
9. an expression system for monoclonal antibody, is transfected into constructing host cell by the construct described in the arbitrary claim of claim 7-8 and forms.
10. the preparation method of the anti-CTLA-4 human antibody as described in claim as arbitrary in claim 1-3, comprise the steps: under the condition of the described antibody of applicable expression, cultivate the expression system of monoclonal antibody according to claim 9, thus give expression to described monoclonal antibody, be isolated and purified with described monoclonal antibody.
The purposes of anti-CTLA-4 human antibody as described in 11. claims as arbitrary in claim 1-3 on preparation CTLA-4 molecule blocking medicine.
12. 1 kinds of pharmaceutical compositions, comprise the described anti-CTLA-4 human antibody for the treatment of significant quantity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410838544.5A CN104479019B (en) | 2014-12-26 | 2014-12-26 | anti-CT L A-4 humanized antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410838544.5A CN104479019B (en) | 2014-12-26 | 2014-12-26 | anti-CT L A-4 humanized antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104479019A true CN104479019A (en) | 2015-04-01 |
| CN104479019B CN104479019B (en) | 2020-07-21 |
Family
ID=52753637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410838544.5A Active CN104479019B (en) | 2014-12-26 | 2014-12-26 | anti-CT L A-4 humanized antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104479019B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019096137A1 (en) * | 2017-11-14 | 2019-05-23 | 拜西欧斯（北京）生物技术有限公司 | Hybridoma comprising immune checkpoint inhibitor, preparation method for same, and applications thereof |
| US10449251B2 (en) | 2014-08-01 | 2019-10-22 | Akeso Biopharma, Inc. | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses |
| US11479608B2 (en) | 2016-08-23 | 2022-10-25 | Akeso Biopharma, Inc. | Anti-CTLA4 antibodies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102134276A (en) * | 2010-01-22 | 2011-07-27 | 上海抗体药物国家工程研究中心有限公司 | Chimeric antibody resisting CTLA-4 (Cytotoxic T Lymphocyte Antigen) |
| CN102766210A (en) * | 1999-08-24 | 2012-11-07 | 梅达里克斯公司 | Human CTLA-4 antibodies and their uses |
-
2014
- 2014-12-26 CN CN201410838544.5A patent/CN104479019B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102766210A (en) * | 1999-08-24 | 2012-11-07 | 梅达里克斯公司 | Human CTLA-4 antibodies and their uses |
| CN102134276A (en) * | 2010-01-22 | 2011-07-27 | 上海抗体药物国家工程研究中心有限公司 | Chimeric antibody resisting CTLA-4 (Cytotoxic T Lymphocyte Antigen) |
Non-Patent Citations (2)
| Title |
|---|
| DARIAVACH,P: "Homo sapiens Ig superfamily CTLA-4 mRNA, complete cds", 《GENBANK》 * |
| 许静: "抗CTLA-4嵌合抗体的制备及生物活性鉴定", 《现代免疫学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449251B2 (en) | 2014-08-01 | 2019-10-22 | Akeso Biopharma, Inc. | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses |
| US11291720B2 (en) | 2014-08-01 | 2022-04-05 | Akeso Biopharma, Inc. | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses |
| US11479608B2 (en) | 2016-08-23 | 2022-10-25 | Akeso Biopharma, Inc. | Anti-CTLA4 antibodies |
| WO2019096137A1 (en) * | 2017-11-14 | 2019-05-23 | 拜西欧斯（北京）生物技术有限公司 | Hybridoma comprising immune checkpoint inhibitor, preparation method for same, and applications thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104479019B (en) | 2020-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104479020A (en) | Anti-PD-1 (programmed cell death-1) humanized antibody | |
| CN109906232B (en) | Multispecific antibody molecules comprising lambda light chain and kappa light chain | |
| CN109071627B (en) | CD8 binding agents | |
| JP7425604B2 (en) | Anti-CTLA4-anti-PD-1 bifunctional antibodies, pharmaceutical compositions and uses thereof | |
| Williams et al. | Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy | |
| JP7262597B2 (en) | Bispecific antibodies and methods of making and using the same | |
| CN109069573A (en) | In conjunction with the single domain antibody of CD20 | |
| EA036779B1 (en) | Anti-pd-1 monoclonal antibody and obtaining method therefor | |
| CN108884164A (en) | For immunotherapy through modified cells | |
| US11390688B2 (en) | Anti-PCSK9 monoclonal antibody | |
| US20230242876A1 (en) | Bifunctional molecule and use thereof | |
| JP2019514355A (en) | Anti-human PD-1 humanized monoclonal antibody and application | |
| CN106589129A (en) | Three-function molecule combining CD19, CD3 and CD28 and application of three-function molecule | |
| CN117285642A (en) | Guidance and navigation control proteins and methods of making and using the same | |
| WO2017070943A1 (en) | Bispecific antibody, and manufacturing method and use thereof | |
| CN112538116B (en) | Group of 4-1BB monoclonal antibodies and medical application thereof | |
| US10563208B2 (en) | Co-expression plasmid | |
| CN104479019A (en) | Anti-CTLA-4 humanized antibody | |
| KR20240046224A (en) | Bispecific antibodies and their uses | |
| CN108264560A (en) | The bifunctional molecule of combination CD3 and CD28 a kind of and its application | |
| CN104558193B (en) | A kind of bispecific antibody preparation method and application of targeted mouse T lymphocyte CD3 and human tumor antigen HER2 | |
| WO2024022008A1 (en) | Anti-siglec-15 monoclonal antibody, and antigen-binding fragment and use thereof | |
| EP3101035A1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
| WO2023045370A1 (en) | Monoclonal antibody targeting tigit | |
| KR20240021289A (en) | Bispecific antibody binding to BCMA and CD3 and its production method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 303 and 304, Building No. 1999, Zhangheng Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai, 201210 Applicant after: Shanghai fugrand hilink biotechnology Limited by Share Ltd Address before: Room 724, 7th floor, 780 Cailun Road, Zhangjiang High-tech Park, Pudong New Area, Shanghai 201210 Applicant before: Shanghai Henlius Biotech Co. Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |